Skip to main content
. 2019 Jun 19;10:363. doi: 10.3389/fendo.2019.00363

Table 1.

Clinicopathological characteristics of 353 PTMC patients.

Clinicopathological characteristics Value
Sex (M/F) 89/264
Age (Y), Mean ± SD (range) 45.9 ± 11.6
    ≥45, n (%) 181 (51.3%)
     <45, n (%) 172 (48.7%)
Primary tumor
    Tumor size (mm), Mean±SD (range) 5.9 ± 2.6
     ≤ 5, n (%) 177 (50.1%)
    >5, n (%) 176 (49.9%)
    BRAF mutation*, n (%) 34 (96.0%)
    Multifocality, n (%) 98 (27.8%)
    ETE, n (%) 38 (10.8%)
    Vascular invasion, n (%) 9 (2.5%)
LNM, n (%)
    CLNM only 93 (26.3%)
    CLNM and LLNM 13 (3.7%)
    Without LNM 157 (44.5%)
    Unknown 90 (25.5%)
Surgery, n (%)
    Lobectomy+CND 78 (22.1%)
    TT+CND 170 (48.2%)
    TT+CND+LND 15 (4.2%)
    Lobectomy or partial thyroidectomy 90 (25.5%)
Recurrence, n (%) 21 (5.9%)
    LNs 12 (3.4%)
    Thyroid bed 4 (1.1%)
    LNs and thyroid bed 4 (1.1%)
    Lung 1 (0.3%)

PTMC, papillary thyroid microcarcinoma; M, male; F, female; Y, year; SD, standard deviation; ETE, extrathyroidal extension; LNM, lymph node metastasis; CLNM, central lymph node metastasis; LLNM, lateral lymph node metastasis; TT, total thyroidectomy; CND, central neck dissection; LND, lateral neck dissection; LN, lymph node.

*

BRAF mutation analysis was started in 2017 and it was performed in 39 patients with PTC.